Therapy For Intermediate Risk Patients
The COG research protocol AHOD0031 was designed for intermediate risk Hodgkin lymphoma and included the following patients:
| Intermediate Risk Hodgkin Lymphoma: |
Stage IA or IIA with bulky disease
Stage IB or IIB disease
Stage IIIA disease |
The aim of this study was to:
- Evaluate response-based therapy
- Evaluate dose-intensive therapy
- To improve outcome and reduce the incidence of long term complication
- Link with COG biological studies
Outline of therapy:
Initial 2 cycles of ABVE-PC - (dose intensification - each cycle was 21 days). G-CSF used for support.
ABVE-PC |
A = Doxorubicin (Adriamycin) B = Bleomycin V = Vincristine E = Etoposide P = Prednisone C = Cyclophosphamide |
Rapid Early Responders:
1. Received another 2 cycles of ABVE-PC
2. Then (after 4 cycles of ABVE-PC) had been given - if there was a complete response, RERs were randomized to receive involved field radiation therapy (IFRT) or no further treatment.
Partial Responders:
Patients who achieved:
- a Very Good Partial Response (VGPR)
- Partial Response (PR)
- Stable Disease (SD)
Slow Early Responder randomized either to standard arm (2 further cycles) or augmented arm (4 further cycles including 2 non-cross reacting cycles) of chemotherapy.
All were given involved field RT
Progressive disease:
These patients were taken off the study and treated as per a high risk protocol
AHOD0031 was closed in 2009 as it had met accrual requirements.
Preliminary results to be presented at ASH Meeting 2011:
"Early response to chemotherapy is important in the optimization of subsequent treatment intensity in patients with HL."
